Der allererste Cannabis Wert in Kanada!

Canopy Growth Expands Westward: Introducing TweeSMITHS FALLS, ON, April 3, 2017 /CNW/ - Canopy Growth Corporation (TSX: WEED) ("Canopy Growth" or "the Company"), is pleased to announce that the Company has entered into an agreement to acquire rTrees Producers Limited ("rTrees") ("the Agreement"). rTrees is a late-stage ACMPR applicant based in Yorkton, Saskatchewan.

Leveraging the award-winning emerging global brand, Tweed, and paying tribute to the vast prairie grasslands, rTrees will operate as Tweed Grasslands, producing high quality Western-grown products to support the Tweed brand and the new flagship Tweed Main Street online store.

"Finding the right opportunity to expand our footprint to Western Canada has been an important priority for our team," said Bruce Linton, Chairman & CEO, Canopy Growth. "We are proud to bring the Tweed reputation for high quality cannabis and engaging customer care to Western Canada, partnering with some of the early pioneers in Canada's legal medical cannabis system."

Tweed Grasslands brings under the canopy a 90,000 sq. ft state-of-the-art indoor growing facility that is presently 20% built-out and serviced by low cost energy and water infrastructure. A pre-license inspection, one of the last steps in the licensing process, was conducted by Health Canada in March 2017.  Sitting on over 11 acres, it is estimated that the Tweed Grasslands facility can expand to over 300,000 sq. ft. in the future.  Tweed Grasslands also adds a talented team, all with Western Canadian roots, that have been involved in the federally regulated cannabis space for the last seventeen years.

"We are excited to be joining forces with Canopy Growth, a company that shares our vision for the future of cannabis," said Andrew MacCorquodale, President & CEO, rTrees. "By merging our skills and experience with the proven operational expertise of Tweed, we will be in a great position to ensure that consumers from Western Canada have reliable access to high-quality, locally grown and produced products from a recognized global brand."

The Company continues to view capacity enhancements as a core aspect of building on its leadership position in the expanding medical cannabis market. With a pending domestic recreational market in Canada as well as increasingly more medical cannabis opportunities internationally, this acquisition supports capacity requirements by adding substantially to the Company's existing growing platform.

The acquisition is subject to approval by the Toronto Stock Exchange and by rTrees shareholders at an upcoming special shareholder meeting.  Upon the signing of the Agreement, rTrees shareholders representing ownership of [82] % of the shares of rTrees, have entered into irrevocable lock-up agreements in favour of the transaction. The acquisition is expected to close on or about May 1, 2017.

On closing, the Company will issue 698,901 common shares and up to another 2,795,604 common shares will be held in escrow and issued if, and when, specific licensing and capacity expansion related milestones are achieved, for a total of up to 3,494,505 shares on successful completion of all milestones.

Here's to Future (Grasslands) Growth.

About Canopy Growth Corporation
Canopy Growth is a world-leading diversified cannabis company, offering diverse brands and curated cannabis strain varieties in dried and oil extract forms.  Through its wholly?owned subsidiaries, Canopy Growth operates numerous state-of-the-art production facilities with over half a million square feet of indoor and greenhouse production capacity.  Canopy Growth has established partnerships with leading sector names in Canada and abroad.  For more information visit www.canopygrowth.com.

Notice Regarding Forward Looking Statements
This news release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth Corporation, Tweed Inc., Tweed Farms Inc., Mettrum Health Corp., or Bedrocan Canada Inc. to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Examples of such statements include future operational and production capacity, the impact of enhanced infrastructure and production capabilities, and forecasted available product selection.  The forward-looking statements included in this news release are made as of the date of this news release and Canopy Growth Corp. does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.



SOURCE Canopy Growth Corporation  
d Grasslands

http://www.newswire.ca/news-releases/...eed-grasslands-617937373.html  

Am 20.4 soll angeblich Cannabis in Kanada legalisiert werden. Wie safe ist das? Hat jemand Infos? VG  

am 10. April erfolgen. Legal soll es dann ab 01. Juli 2018 sein (soweit zumindest die Info die ich von Freunden aus Kanada habe).

 

Für die Antwort.  

Source:https://www.canadianinsider.com/...earch=WEED%20%7C%20Canopy%20Growth

 

Man geht von sinkenden Kursen aus?  

Canopy Growth CraftGrow Opens Platform to Craft Cannabis Producers

Say Hello to CraftGrow: Tweed Bringing Three New Producers to Main Street

Licensed Producers AB Laboratories Inc., part of Invictus MD, JWC Ltd. and Canada?s Island Garden to sell distinct small batch cannabis through Tweed Main Street, bringing new variety and diversity to over 50,000 registered patients.

SMITHS FALLS, ON, April 19, 2017 /CNW/ ? Canopy Growth Corporation (TSX: WEED) (?Canopy Growth? or ?the Company?), is pleased to announce the launch of Tweed?s curated CraftGrow line, which brings high quality cannabis grown by a diverse set of producers to Tweed Main Street?s customers. In line with the level of variety customers have come to expect, Tweed will proudly showcase the history and unique growing methods of each CraftGrow producer.
?Our company recognizes the diverse needs of patients and is proud to bring them the highest quality products that we grow in our own facilities, while introducing them to producers that each bring a unique offering forward,? said Bruce Linton, Chairman & CEO, Canopy Growth. ?Telling the story of cannabis cultivators, big and small, is essential to a successful market for medical cannabis.?

Having put together the infrastructure of over 100 customer care staff, as well as packing and fulfilment staff capable of shipping thousands of orders a day, we are in a unique position to support smaller producers getting to market, and to help patients find the products they need from an ever wider selection.
By participating in CraftGrow, Access to Cannabis for Medical Purposes Regulations (?ACMPR?) license applicants and Licensed Producers can utilize components of the Company?s platform including high quality genetics sourced from around the world, industrial scale cannabis oil extraction infrastructure, a rigorous product Quality Assurance program, the Tweed Main Street online marketplace as well as award winning customer care and call centre capabilities. Access to these Canopy Growth platform components can be expected to significantly reduce the resources that new entrants are required to invest to enter the market and help get them get to market much faster to the benefit of all medical cannabis patients.

As a staring point, three distinct partners are joining CraftGrow, all with different growing styles and approaches to cannabis. They are: AB Laboratories Inc., Canada?s Island Garden, and JWC Ltd.

?As a fairly new Licensed Producer with a market capitalization less than our peers, we are able to utilize Canopy Growth?s existing infrastructure giving us access to a wider market,? said Dan Kriznic, Chairman & CEO, Invictus MD, on behalf of AB Laboratories. ?By collaborating with Canopy Growth, we are committed to improving access to multiple high quality brands through a better online experience.?

Prince Edward Island-based partner, Canada?s Island Garden will sell many of its products under the CraftGrow banner as a way to introduce themselves to a wider market.
We are proud of our operations here in PEI and as one of the few producers based in Atlantic Canada we see CraftGrow as a way to raise our profile and bring a little bit of PEI to the rest of Canada.

Finally, JWC will join CraftGrow with a vision for advancing the technological side of cannabis production. ?JWC is happy to participate in the CraftGrow program. It is a unique opportunity to showcase our products and techniques, and a unique opportunity to highlight and share our advanced Aeroponic growth techniques. Technology is a vital part of this industry, and it is through partnerships such as this that we are able to rapidly advance the technological tools at our disposal,? said Nathan Woodworth, President of JWC Ltd.

By choosing to partake in CraftGrow, producers with cultivation and sales licenses can furnish their harvests to Tweed, on a wholesale basis for sale through Tweed Main Street. All CraftGrow cannabis is subject to Tweed?s rigorous Quality Assurance program, including accredited lab testing, prior to being approved for sale.

Licensed producers and pre-license applicants interested in the CraftGrow program are encouraged to contact Devin McGee (devin.mcgee@canopygrowth.com) or Owen Smith (owen.smith@canopygrowth.com). More information and more cannabis variety will be available soon at tweedmainstreet.com

Here?s to Future Craft Growth.

https://www.tweedmainstreet.com/  

Tweed Expands Product Offering with Launch of FORIA

Canada NewsWire

SMITHS FALLS, ON, April 20, 2017

SMITHS FALLS, ON, April 20, 2017 /CNW/ - Tweed Inc. ("Tweed"), a wholly-owned subsidiary of Canopy Growth Corporation (TSX: WEED) ("Canopy Growth") today expanded its product line with the introduction of FORIA. We're either nine months and 24 days early or two months and six days late - it's all about perspective. Happy 4-20.

For more information on FORIA, please visit www.tweedmainstreet.com.

And if you're perusing the Main Street site today, why not snag a new t-shirt for $4.20. Today only for all of our friends.

About Canopy Growth Corporation
Canopy Growth is a world-leading diversified cannabis company, offering diverse brands and curated cannabis strain varieties in dried and oil extract forms. Through its wholly?owned subsidiaries, Canopy Growth operates numerous state-of-the-art production facilities with over half a million square feet of indoor and greenhouse production capacity. Canopy Growth has established partnerships with leading sector names in Canada and abroad. For more information visit www.canopygrowth.com.

Notice Regarding Forward Looking Statements
This news release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth Corporation, Tweed Inc., Tweed Farms Inc., Mettrum Health Corp., or Bedrocan Canada Inc. to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Examples of such statements include future operational and production capacity, the impact of enhanced infrastructure and production capabilities, and forecasted available product selection.  The forward-looking statements included in this news release are made as of the date of this news release and Canopy Growth Corp. does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.



SOURCE Canopy Growth Corporation  

http://www.auscann.com.au/announcements.html


Why the Auscann Group Holdings Ltd share price has gone nuts today

The Auscann Group Holdings Ltd (ASX: AC8) share price has skyrocketed this morning after emerging from a trading halt.

In early trade the pot stock is up a massive 22% to 71 cents.

What happened?

As I mentioned yesterday, AusCann?s shares went into a trading halt pending an update on its Australian operations.

This morning the company released its update advising that it has been granted a licence to cultivate medicinal cannabis in Australia by the Office of Drug Control, making AusCann one of only a few companies to be granted a licence.

http://www.fool.com.au/2017/05/05/...share-price-has-gone-nuts-today/  

https://www.leafly.com/news/industry/...amid-secretive-license-grants  

Update 10.05.2017: Das Flaggschiff reisst jede Unterstützung, der Durchbruch durch die 200er EMA beschleunigt den Abverkauf sogar. Der RSI ist nun stark überverkauft und signalisiert eine etwaige baldige kurzfristige Entspannung. Wird selbst der Bereich bei 7,3-7,65 unterschritten wäre das nächste technische Kursziel erst wieder bei ca. 5,5CAD zu suchen. Erst Kurse > 8,8 respektive 9,6 entspannen das angeschlagene Chartbild.
Gesamte Analyse hier: http://www.marihuana-aktien.de/news/chartupdate-lp-s/

 

Hoffe, die Trendwende wird eingeläutet. Mein Ziel ist aber hier langfristig dabei zu bleiben...bin gespannt!  

...weiß einer warum? News gab es keine...  

https://www.newcannabisventures.com/...f-new-medical-cannabis-market/


Auscann: http://www.auscann.com.au/investor-centre/asx-announcements/2017.html

Canopy: https://www.tweedmainstreet.com/

https://markets.ft.com/data/equities/tearsheet/forecasts?s=WEED:TOR  

https://web.tmxmoney.com/...ewsid=7859606882811336&qm_symbol=WEED  

https://www.stockwatch.com/News/...81444&symbol=WEED&region=C  

https://web.tmxmoney.com/...ewsid=8787346410663443&qm_symbol=WEED

Sicher wieder rot, das wird dem markt nicht genügen und der Market Cap wohl auch nicht gerecht - war fast zu erwarten ;)  

Der Kurs wenn canopy über Kooperation in Deutschland mit zur Lizenz eines Partners gehört?  

http://www.auscann.com.au/investor-centre/asx-announcements/2017.html

http://clients3.weblink.com.au/pdf/AC8/01879210.pdf  

Auscann has been granted an australian medicinal cannabis manufacturing licence by office of drug control  

zitat:"Canopy Growth Corp. has released its consolidated financial results for the first quarer/First Quarter 2018 Highlights.....
   First quarter revenue was $15.9 million, a 127% increase over the three month period ended June 30, 2016 when revenue totaled $7.0, and an 8% increase over fourth quarter of fiscal 2017 revenues of $14.7 million;
   Launching the Tweed Main Street online store, which required moving individual Tweed, Mettrum and Bedrocan e-commerce sites offline and the migration of customers to a single database and new e-commerce platform, reduced sales activity over a period of approximately 10 business days in April. Reduced sales activity in the month of April negatively impacted revenues in the first quarter fiscal 2018. In addition, Mettrum growing operations were mostly inactive through thelater half of the fourth quarter fiscal 2017 and first quarter fiscal 2018 while being integrated with new standard operating and quality control procedures resulting in lower availability for sale of Mettrum branded products in the first quarter fiscal 2018 -Sold 1,830 kilograms and kilogram equivalents; an 86% increase over first quarter fiscal 2017;
   Harvested 5,575 kg, mostly attributed to the Tweed Farms greenhouse harvest, compared to 1,882 kg during the same period last year, representing a 196% increase over first quarter fiscal 2017 -The weighted average cost per gram of cultivation to harvest and post-harvest costs before shipping and fulfilment was $1.28 per gram. This compares to $1.64 per gram in the first quarter of last year and to $1.46 per gram in the fourth quarter of last year;
   The first quarter gross margin before non-cash gains or losses was $9.0 million or 57% of revenue as compared to $4,205 and 60% of revenue in the same quarter of last year, and 64% for the fourth quarter of fiscal 2017. The first quarter gross margin before non-cash gains or losses includes the costs associated with resetting the Mettrum grow operations and centralizing all shipping and fulfilment activities in Smiths Falls as part of the "one store" implemented in the first quarter, as well as costs associated with subsidiaries that are not yet cultivating or selling cannabis. Excluding these costs totaling $1.4 million, the gross margin before non-cash gains or losses would have been $10.4 million or 66% of revenue;
   Net loss in the first quarter of fiscal 2018 amounted to $4.4 million, or $0.03 per basic and diluted share, compared to a net loss of $3.9 million, or $0.04 per basic and diluted share in the first quarter of fiscal 2017;
   Launched the sale of Canada's first encapsulated cannabis oil soft gels on June 19, 2017;
   Partners AB Laboratories Inc., Canada's Island Garden, JWC Ltd, and PUF Ventures Inc. joined our CraftGrow program during quarter; Canada's Island Garden products released for sale on June 24, 2017;
   On June 24, 2017, announced flowering capacity increases at Smiths Falls and Bowmanville facilities, of 33% and 200%, respectively; Also announced industrial cannabis oil extraction system now operational;
   $115.5 million in cash and cash equivalents at quarter end .. " ENDE Zitat

Subsequent to First Quarter 2018 .. > siehe LINK Quellenangabe

Source/Quelle:https://www.stockwatch.com/News/...94794&symbol=WEED&region=C  

CEO von "Canopy Growth" Bruce Linton im Interview vom 7. September 2017

http://aktien-boersen.blogspot.de/2017/09/...wth-bruce-linton-im.html  

https://www.newcannabisventures.com/...spain-for-cannabis-production/

Canopy Growth Partner mit Alcaliber in Spanien für Cannabis Produktion

SMITHS FALLS, ON und MADRID, Sept. 11, 2017 / CNW / - Canopy Growth Corporation (TSX: WEED) (OTC: TWMJF) ("Canopy Growth" oder die "Company") und ihre hundertprozentige Tochtergesellschaft Spektrum Cannabis GmbH ( "Spektrum") freuen sich, mit Alcaliber, SA ("Alcaliber"), einem führenden Akteur in der internationalen Pharmaindustrie mit Sitz in Spanien, einen Liefervertrag zu verkünden. Alcaliber ist spezialisiert auf Forschung und Entwicklung, Zucht und Anbau sowie die Extraktion, Reinigung und Aufbereitung von Betäubungsmitteln ("NRMs") und Active Pharmaceutical Ingredients ("APIs"). Diese Vereinbarung ist die erste ihrer Art zwischen einem kanadischen Cannabis-Unternehmen und einem bedeutenden, etablierten internationalen Pharma-Spieler.
Die Einnahme dieses Vertrages mit einem großen, anerkannten europäischen Partner wie Alcaliber, mit einem bewährten Hintergrund in kontrollierten Substanzen und der Fähigkeit, pflanzliche Medikamente zu produzieren, verfestigt unser Engagement für diversifizierte Produktionskapazitäten nicht nur in Kanada, sondern auch neue und aufkommende Cannabismärkte.Diese Vereinbarung gibt uns zusätzliche Ressourcen, um aggressiv in den europäischen Markt einzutreten, wo gesetzlich gesetzlich zugelassen ist, während wir weiterhin daran arbeiten, unseren eigenen komplementären Produktionsstandort für den Cannabisanbau, die Wertschöpfung der Ölförderung und die Softgelproduktion in der Europäischen Union zu etablieren.Alcaliber hat eine Lizenz zur Kultivierung, Herstellung, Herstellung, Ausfuhr / Einfuhr und Vermarktung von Cannabis für medizinische und wissenschaftliche Zwecke durch die spanische Agentur für Arzneimittel und Medizinprodukte erhalten. Als Ergebnis dieser Vereinbarung gewährt Canopy Growth and Spektrum Alcaliber eine Lizenz, um bestimmte Stämme und Samen zu verwenden, um in Alcalibers Einrichtungen zum Verkauf weltweit angebaut und angebaut zu werden.Alcaliber ist begeistert von pharmazeutischem Cannabis und unsere Vereinbarung mit Canopy Growth und Spektrum ist eine perfekte Symbiose. Es gibt eine klare Nachfrage nach pharmazeutischen Cannabis, die nach pharmazeutischen Standards produziert werden, und das Know-how, das wir seit über 40 Jahren mit der Herstellung von Narkotika-Derivaten entwickelt haben, kombiniert mit Canopy Growth und Spektrum's Cannabis-Erlebnis wird ein großer Fortschritt für die Industrie sein.Als bewährter weltweit führender Anbieter von Arzneimitteln mit einer etablierten Erfolgsbilanz bei der Herstellung von NRMs und APIs sowie bestehenden Produktionsinfrastrukturen und Vertriebsnetzen hat das Engagement von Alcaliber das Potenzial, die strategische Expansion von Spektrum auf dem europäischen Markt sinnvoll zu beschleunigen...  

Canopy Growth to Supply Australia Through AusCann Group Holdings

https://www.newcannabisventures.com/...hrough-auscann-group-holdings/

Canopy Growth bietet weitere internationale Updates

SMTP-FALLS, ON, Sept. 13, 2017 / CNW / - Die Canopy Growth Corporation (TSX: WEED) (OTC: TWMJF) ("Canopy Growth" oder die "Gesellschaft") freut sich, bekannt zu geben, dass sie einen Liefervertrag abgeschlossen hat mit der AusCann Group Holdings Ltd.  (ASX: AC8) (OTC: ACNNF) ("AusCann"), wobei das Canopy Growth als exklusiver Lieferant von medizinischem Cannabis von AusCann für den australischen Markt fungiert, beginnend mit dem Transfer einer Reihe von Arzneimitteln für die Forschung und Kommerzialisierung in Australien.
Besuchen Sie das Canopy Growth Corp Investor Dashboard und bleiben Sie auf dem Laufenden mit datengesteuerten, faktenbasierten Due Diligence für aktive Händler und Investoren.
Canopy Growth bietet weitere internationale Updates

SMTP-FALLS, ON, Sept. 13, 2017 / CNW / - Die Canopy Growth Corporation (TSX: WEED) (OTC: TWMJF) ("Canopy Growth" oder die "Gesellschaft") freut sich, bekannt zu geben, dass sie einen Liefervertrag abgeschlossen hat mit der AusCann Group Holdings Ltd.  (ASX: AC8) (OTC: ACNNF) ("AusCann"), wobei das Canopy Growth als exklusiver Lieferant von medizinischem Cannabis von AusCann für den australischen Markt fungiert, beginnend mit dem Transfer einer Reihe von Arzneimitteln für die Forschung und Kommerzialisierung in Australien.

Der australische Markt präsentiert weiterhin attraktive Wachstumschancen für medizinischen Cannabis und durch die Minderheitsbeteiligung der Gesellschaft und eine ausgezeichnete Arbeitsbeziehung mit AusCann ist es in der Lage, dieses Potenzial für seine Aktionäre zu realisieren.

Diese Vereinbarung ist ein positiver Schritt, um australischen Patienten den Zugang zu hochwertigen Cannabinoid-Medikamenten zu ermöglichen. Ich freue mich, mit dieser Partnerschaft voranzukommen und weiterhin die Produktionsskala der bestehenden Partner zu nutzen, um unsere eigene Vertriebsfunktion und Marktpräsenz zu beschleunigen.Als ein aufstrebender Markt wird die Größe dieser Erstversendung nicht voraussichtlich die Fähigkeit des Kunden beeinflussen, das Produkt durch Tweedmainstreet.com zu erwerben, wo sich die konsequente Produktverfügbarkeit durch eine starke Produktion aus der Canopy-weiten Produktionsplattform stabilisiert hat.

Diese Vereinbarung, die Canopy Growth weiterhin die Möglichkeit hat, andere australische Chancen zu verfolgen, folgt einer kürzlich veröffentlichten Ankündigung vom 11. September 2017, in der das Unternehmen eine strategische Partnerschaft mit Alcaliber SA ("Alcaliber"), einem führenden Pharma-Produzenten, der im vergangenen Jahr exportierte, angekündigt hat 125 Tonnen Alkaloide in 40 Länder auf der ganzen Welt, was einen Marktanteil von 20% für Betäubendes Rohmaterial (NRM) darstellt.

Ob Europa, Südamerika, Australien oder zu Hause, das Canopy Growth arbeitet hart daran, seine anerkannte, qualitativ hochwertige Genetik in die Welt zu bringen.

Hier ist zu zukünftigem Wachstum unten unter.  

https://www.newcannabisventures.com/...y-growth-as-cannabis-supplier/

New Brunswick Selects Canopy Growth as Cannabis Supplier

Canopy Growth and

... (automatisch gekürzt) ...

https://www.newcannabisventures.com/...y-growth-as-cannabis-supplier/